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Abstract.
Background: Motor complications are a consequence of the chronic dopaminergic treatment of Parkinson’s disease (PD) and
include levodopa-induced dyskinesia (LIDs) and motor fluctuations (MF). Currently, evidence is on lacking whether patients
with GBA-associated PD differ in their risk of developing motor complications compared to the general PD population.
Objective: To evaluate the association of GBA carrier status with the development of LIDS and MFs from early PD.
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Methods: Motor complications were recorded prospectively in 884 patients with PD from four longitudinal cohorts using
part IV of the UPDRS or MDS-UPDRS. Subjects were followed for up to 11 years and the associations of GBA mutations
with the development of motor complications were assessed using parametric accelerated failure time models.
Results: In 439 patients from Europe, GBA mutations were detected in 53 (12.1%) patients and a total of 168 cases of LIDs
and 258 cases of MF were observed. GBA carrier status was not associated with the time to develop LIDs (HR 0.78, 95%
CI 0.47 to 1.26, p = 0.30) or MF (HR 1.19, 95% CI 0.84 to 1.70, p = 0.33). In the American cohorts, GBA mutations were
detected in 36 (8.1%) patients and GBA carrier status was also not associated with the progression to LIDs (HR 1.08, 95%
CI 0.55 to 2.14, p = 0.82) or MF (HR 1.22, 95% CI 0.74 to 2.04, p = 0.43).
Conclusion: This study does not provide evidence that GBA-carrier status is associated with a higher risk of developing
motor complications. Publication of studies with null results is vital to develop an accurate summary of the clinical features
that impact patients with GBA-associated PD.
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INTRODUCTION
The core motor features of Parkinson’s disease
(PD) are bradykinesia, rigidity, and tremor. These
features are usually improved by treatment with lev-
odopa and patients’ response is well-maintained by
intermittent dosing during waking hours, especially
in the early stages of disease. However, long-term
dopaminergic therapy, particularly with levodopa,
often results in the development of motor compli-
cations. These are typified by a reduction in the
duration and reliability of the treatment related motor
improvements, termed motor fluctuations (MF), and
the emergence of involuntary movements, termed
levodopa-induced dyskinesia (LIDs) [1, 2].
Motor complications impact quality of life and
affect the vast majority of patients by 15–20 years
of treatment, although the time it takes for them to
first develop differs considerably [1, 3, 4]. Several
factors have been linked to the development of MF
or LIDs, including female sex, younger age, higher
motor symptom severity at diagnosis, medication
regime, or nonmotor feature severity, including low
mood and high anxiety [5–9].
Mutations in the glucocerebrosidase (GBA) gene,
which encodes the lysosomal enzyme that is deficient
in Gaucher’s disease, are important and common risk
factors for PD. Patients with GBA-associated parkin-
sonism tend to have an earlier age of onset and
develop motor and cognitive impairment faster than
the general PD population [10–13]. Recent work has
assessed the risk of developing motor complications
in GBA-associated PD, with conflicting results. The
first longitudinal study found no association between
GBA carrier status and the development of LIDs [14].
Two later studies found that GBA carriers were at
increased risk of developing LIDs, but their findings
regarding the development of MF were inconsistent
[9, 15]. Given the importance of the proper recogni-
tion of subgroups of patients with PD at increased risk
of motor complications, further studies are needed to
clarify the impact of GBA carrier status on the risk of
MF and LIDs.
This study aimed to examine the association bet-
ween GBA carrier status and the development of
either MF or LIDs over time in large, well charac-
terized and prospectively followed cohorts of com-
munity-based, non-selected patients with PD from
Europe and America. Understanding which groups
of patients with PD are at high risk for motor compli-
cations would be of benefit in terms of prognosis and




In the European dataset, patients with PD were
included from the Norwegian ParkWest study [16],
the Parkinsonism Incidence in North-East Scotland
(PINE) study [17], and the Swedish New Parkinson
Patient in Umeå (NYPUM) study [18]. These cohorts
provide on-going follow-up of population-based inci-
dence studies of all newly diagnosed PD identified in
specific geographic regions, initiated between 2002
and 2009. Briefly, 212 patients were enrolled in the
ParkWest study, 211 in the PINE study, and 182 in
the NYPUM study with a diagnosis of PD guided by
the UK brain bank criteria [19] though not exclud-
ing those with a family history of PD. Only those
with a confirmed clinical or pathological (if post-
mortem examination was performed) diagnosis of
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PD at their latest or final clinical visit were included.
Since enrollment, 71 had a diagnosis other than PD
during follow-up. Further, 57 declined genotyping,
31 have no available DNA sample or DNA was not
extractable, and seven did not consent to follow-up.
The remaining 439 patients were eligible for this
study. At the time of the study, data from clinical
visits for a period of up to ten years were available.
For the American dataset, patients with PD were
included from the Parkinson’s Environment Gene
(PEG) Study. The PEG cohort provides on-going
follow-up of new-onset (up to 5 years after diagnosis)
idiopathic PD cases from three rural California coun-
ties (Kern, Tulare, Fresno) with participants enrolled
in two waves (PEG1 between 2001 and 2007 and
PEG2 between 2010 and 2014) [20]. PD patients
were all recruited as part of the PEG case-control
study through medical groups, neurologists, and pub-
lic service announcements, and a Parkinson’s disease
registry pilot program in these counties. All patients
in PEG were seen by movement disorder specialists
at least once at baseline, many on multiple occa-
sions and during follow-up, and confirmed as having
probable idiopathic PD based on UKBB guidelines
except for the family history criterion. Briefly, 849
patients were enrolled in the case-control study, and
525 patients have participated in prospective follow-
up visits to assess progression (mean follow-up of
4.7 years (SD = 2.8)). Of those not examined dur-
ing follow-up (n = 324), 174 were deceased (54%),
42 refused or could not be re-contacted (13%), and
108 are pending examinations (33%). Included in the
present study were 445 patients who were recruited
within 4.0 years of PD diagnosis, assessed for the
presence of motor complications, and had genetic
information available. At the time of the study, data
from up to three clinical assessments were available
(maximum follow up 11.4 years from diagnosis).
Studies were approved by respective ethical com-
mittees: The Western Norway Regional Committee
for Medical and Health Research Ethics, the Multi-
Centre Research Ethics Committee for Scotland, the
Regional Ethics Review Board in Umeå, and the
UCLA Institutional Review Board. Written informed
consent was signed by all participants.
Clinical assessments
The clinical assessments have been described
in detail before [16–18, 20]. At baseline, gen-
eral medical and neurological examinations and
semi-structured interviews were performed for all
participants to establish medical, drug, and family
history (first-degree relative with PD, self-reported).
Furthermore, all patients were assessed using Hoehn
and Yahr staging [21]. At baseline, patients in Park-
West, PINE, NYPUM and PEG1 were assessed
using the Unified Parkinson’s Disease Rating Scale
(UPDRS) [22] and in PEG2 using the Movement
Disorder Society (MDS)-UPDRS [23]. In PINE,
ParkWest and NYPUM, patients were examined
on PD medications whenever possible, whilst in
PEG patients were examined while functionally off
PD medications (overnight medication withdrawal)
whenever possible for UPDRS part III.
For the European cohorts and PEG1 at baseline,
motor complications were detected using UPDRS
part IV (motor fluctuations, score ≥ 1 on UPDRS
item 36, 37, 38 or 39; and dyskinesias, score ≥ 1 item
32, 33 or 34). For PEG2 and PEG1 follow up visits,
motor complications were detected using MDS-
UPDRS part IV (motor fluctuations, score ≥ 1 on
UPDRS item 4.3 and 4.4; and dyskinesias, score ≥ 1
item 4.1 and 4.2). Home visits were offered in PEG1
to those unable or unwilling to come to the clinic to
minimize attrition bias.
Antiparkinsonian treatment was prescribed and
adjusted throughout the study by a study neurolo-
gist (European dataset) or treating physician (PEG)
according to best clinical judgment. We calculated
levodopa-equivalent doses (LED) in accordance with
published recommendations [24].
Assessment of GBA status
Genomic DNA was isolated from the peripheral
blood of each subject by standard methods. The
presence of GBA variants in the European dataset
has been described in detail [10]: 188 patients of
the ParkWest cohort were characterized by whole
exome sequencing and six non-synonymous variants
were detected (rs76763715/N370S, rs421016/L444P
and rs781152868/Y135C, rs2230288/E326K, rs755
48401/T369M, and rs369068553/V460L) and con-
firmed by direct sequencing of fragments amplified
using primers to specifically amplify the functional
GBA gene and not the pseudogene (Supplementary
Table 1) [10]. These variants were genotyped in
all available European samples using TaqMan sin-
gle nucleotide polymorphism genotyping assay (The-
rmo Fisher Scientific), using ParkWest samples as
controls for each detected genotype. The L444P
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genotype was determined using restriction fragment
length polymorphism (PCR-RFLP) assays and all
mutations confirmed by direct sequencing of the
polymerase chain reaction product (Supplementary
Table 1) [25, 26]. For the PEG dataset, all patients
were characterized by a TruSeq custom ampli-
con panel (Illumina Inc., San Diego, CA), using
paired probes designed to hybridize to unique target-
specific sequences, including the GBA gene, and
PCR amplification to enrich the target regions.
11 non-synonymous variants were detected in the





tary Table 2). All amino acid substitutions are
numbered excluding the 39-residue signal peptide.
For the purpose of this study, GBA variants were
classified based on published reports of pathogenic-
ity in Gaucher’s disease (GD) or reported associati-
ons with PD. GBA mutations were classified as
“severe” (L444P, G202R, R257Q, and D409H) if
linked to neuropathic type 1 or 2 Gaucher’s disease
(GD) or “mild” (N370S) if associated with the non-
neuropathic type 1 GD. “Risk” variants have been
reported to increase risk of PD [27, 28] but were
linked to GD only when occurring in conjunction
with other GBA mutations [29]. The remaining
variants are of unknown significance. The initial
classification of mutation severity in association
with GD was based on a published classification
[30] supplemented with more recent evidence from
The Human Gene Mutation Database [31] (http://
www.hgmd.cf.ac.uk/), CliniVar (https://www.ncbi.
nlm.nih.gov/clinvar/), and literature searches (sum-
marized in Supplementary Table 3). Each variant
not classified in GD was subsequently assessed for
association with PD using literature identified in
Pubmed.
Statistical methods
Participants were identified as GBA carriers (with
one or more GBA mutations) or non-carriers (no
GBA mutation). For secondary analysis, we further
subdivided the GBA mutations into severe, mild,
risk factor or unknown significance (Supplemen-
tary Table 2). Because of the small sample size for
the GBA mild subgroup, the mild and risk factor
categories were combined. Between-group differ-
ences were compared using t-tests, Mann-Whitney
tests and χ2-tests as appropriate. Non-parametric
maximum likelihood estimates (NPMLEs) of the sur-
vival distributions were assessed by the expectation-
maximization algorithm [32]. Parametric accelerated
failure time models were applied for the primary sur-
vival analysis, with allowance for interval censoring
and with t = 0 at time of diagnosis. The Weibull model
was deemed optimal (over other parametric mod-
els) for time to MF using both the Akaike and the
Bayesian information criteria. For LIDs the Weibull
model performed similarly to the Gaussian model
and was chosen for consistency and interpretability.
These comparisons were made for models adjusted
for age and sex. Furthermore, log minus log plots
were assessed for the unadjusted models and dis-
played reasonably straight lines. Coefficients from
the Weibull model were transformed into hazard
ratios (HR), which were presented with 95% con-
fidence intervals (CI). Further adjustment for motor
severity at first visit, or ethnicity (American dataset),
or repetition of the models using t = 0 as time of first
visit and including adjustment for disease duration at
time of first visit did not affect the effect sizes (data
not shown). Cox proportional hazards models assum-
ing right-censored data were applied in secondary
analysis to allow for models including time-varying
covariates (PD medication) (analyzed only for Euro-
pean data). The time of event was set to the first visit
MF or LIDs was recorded and censoring was at the
last clinical assessment. There were no substantial
differences between the HRs obtained using Cox pro-
portional hazards models and those transformed from
the Weibull model in unadjusted or adjusted models.
Cox proportional hazards models were next applied
adjusting for age and sex and the time varying med-
ication variables total daily LED, use of dopamine
agonists, or use of levodopa at each annual visit.
Data preparation, descriptive and between group
comparisons were performed in SPSS. NPMLEs
of survival distributions, parametric survival anal-
ysis for interval-censored data and Cox regression
with time-dependent covariates were performed in
R v. 4.0.2 with package survival, functions survfit,
survreg and coxph. The main plots of survival curves
were created with function ggsurvplot of package
survminer.
Data availability
Anonymized data are available on request by any
qualified investigator for purposes of replicating pro-
cedures and results.
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RESULTS
Baseline profile of PD-GBA carriers
This study included 884 patients with PD recruited
to either one of three European cohorts (ParkWest,
PINE or NYPUM; n = 439) or the American PEG
cohort (n = 445). The baseline characteristics of the
cohorts are listed in Supplementary Table 4. The
median age at diagnosis was 70.7 (14.0) years and
70.0 (13.0) years in the European cohorts and PEG
cohort, respectively. The European cohorts com-
prised 60.8% (267) males and the PEG cohort
comprised 61.3% (273) males.
In the European cohorts, GBA variants were iden-
tified in 53 (12.1%) patients [10] and in the PEG
cohorts, GBA variants were identified in 36 (8.1%)
patients (Table 1). The median age of diagnosis in
the GBA carrier group was younger (EUR 66.7 years,
USA 66.0 years) than in the non-carriers (EUR 71.1
years, USA 70.0 years) and the distributions in the
two groups differed significantly in both the Euro-
pean (Mann–Whitney U p = 0.01) and PEG cohorts
(Mann–Whitney U p = 0.03). No further differences
were identified between carriers of a GBA mutation
and non-carriers for demographic or clinical variables
assessed at the first clinical visit (Table 1).
Effect of GBA on the development of motor
complications
We first examined the development of motor com-
plications in 439 participants of the European cohorts.
Of these, 9 patients were only assessed at one clini-
cal visit and were excluded, leaving 430 patients in
the survival analysis. By 10 years of follow-up, 36
(67.9%) of the 53 carriers of any GBA mutation had
developed MF compared to 222 (58.9%) of the 377
non-carriers, and 18 (34.0%) of 53 GBA mutation car-
riers had developed LIDs compared to 150 (39.8%)
of the 377 non-carriers. Parametric accelerated fail-
ure time models were applied to assesses the impact
of GBA carrier status on the time to develop motor
complications. The risk of developing MF or LIDs
in carriers of a GBA-mutation was not different com-
pared to non-carriers in unadjusted analysis (MF: HR
1.22, 95% CI 0.86 to 1.74, p = 0.27; LIDs: HR 0.78,
95% CI 0.48 to 1.28, p = 0.33) or when controlling for
age and sex (Table 2; Fig. 1). Repetition of the model
excluding those GBA variants of unknown signifi-
cance did not affect the effect sizes (data not shown).
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Table 2
Survival analysis for the development of motor complications
Progression to MF Progression to LIDs
HR (95% CI) p HR (95% CI) p
European cohorts
GBA carrier† 1.19 (0.84 to 1.70) 0.33 0.78 (0.47 to 1.26) 0.30
Severe mutation carriers† 1.66 (0.68 to 4.07) 0.26 0.33 (0.05 to 2.35) 0.43
Mild mutations and risk factor carriers† 1.17 (0.80 to 1.72) 0.41 0.81 (0.49 to 1.36) 0.27
USA cohorts
GBA carrier† 1.22 (0.74 to 2.04) 0.43 1.08 (0.55 to 2.14) 0.82
Severe mutation carriers† 0.60 (0.08 to 4.41) 0.62 1.36 (0.19 to 10.03) 0.76
Mild mutations and risk factor carriers† 1.21 (0.69 to 2.11) 0.51 1.19 (0.57 to 2.46) 0.64
†Non-carrier group used as reference group for statistical analysis. Adjusted for age and sex. CI, confidence interval; HR, hazard ratio: MF,
motor fluctuations, LIDs, levodopa induced dyskinesias.
Fig. 1. Nonparametric maximum likelihood estimates of the survival distributions for onset of motor fluctuations (MF) and levodopa-induced
dyskinesias (LIDs) in the European data set (A and B) or the American dataset (C and D). Time from Parkinson’s disease diagnosis is shown
in years. Subjects were grouped into carriers of a GBA variant (blue) or non-carriers (yellow).
mutations or mild and risk factor GBA mutations on
the time to develop motor complications compared to
non-carriers revealed no statistically significant asso-
ciation with either MF or LIDs (Table 2). Finally, we
applied Cox proportional hazards regression models
including time-varying covariates to account for the
possible effects of medication regime over the course
of PD. Inclusion of time varying total LED, use of
levodopa or use of dopamine agonist did not alter
the lack of association of GBA carrier status with the
development of either MF or LIDs (data not shown).
To validate these findings, we next assessed the
development of motor complications in 445 par-
ticipants from the PEG cohort. 440 patients were
assessed for MF and 445 patients for LIDs during
the study. 10 patients reported MF and 3 LIDs at the
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time of diagnosis and were excluded from the survival
analysis. Parametric accelerated failure time models
were then applied to assess the association of GBA
status with the development of motor complications
from the time of PD diagnosis, and showed that in the
American cohorts GBA-carriers were not at increased
risk of developing MF or LIDs in comparison to the
non-carriers in unadjusted analysis (MF: HR 1.18,
95% CI 0.72 to 1.96, p = 0.51; LIDs: HR 1.08, 95% CI
0.54 to 2.13, p = 0.83) or when controlling for age, sex
(Table 2, Fig. 1C, D). Similarly, the effect sizes did not
change when the analysis was repeated after exclud-
ing the variants of unknown significance, or when
analysing the impact of either severe GBA mutations
or mild and risk factor GBA mutations compared to
non-carriers (data not shown).
DISCUSSION
In this study we explored the relationship between
GBA carrier status and the long-term development
of motor complications in patients with PD fol-
lowed prospectively from the early stages of disease.
Our findings from both European and American PD
populations do not support an association of GBA
mutations with an increased risk of developing MF
or LIDs. These data have important implications of
fully understanding the impact of GBA mutations on
the prognosis of PD.
GBA-PD is associated with a younger onset of PD
and a more aggressive disease course, including faster
progression of motor impairment measured using the
UPRDS part III [10–13, 33–35], and it has been sug-
gested that this subgroup of patients may also be at
increased risk of developing motor complications.
Motor complications negatively affect patients’ qual-
ity of life and progression of these symptoms can
trigger consideration of advanced treatment options
[36]. Further, there is an increasing interest in using
genetic stratification to improve the design of clinical
trials, with the first trials using GBA as an inclusion
criterion already completed [37]. Accordingly, it is
important to establish which factors put patients at
increased risk of developing motor complications.
The majority of previous work assessing motor
complications in GBA-associated PD is from cross-
sectional studies. Of seven studies [38–44], none
found an association of GBA-carrier status with MF
and only two [43, 44] with a higher frequency of LIDs
at the time of examination. Few longitudinal cohort
studies have addressed how motor complications
develop over the course of GBA-associated PD com-
pared to the general PD population [9, 14, 15]. In
agreement with the findings of the current study, two
did not show an association between GBA carrier sta-
tus and the time to develop LIDs [14] or MF [9].
Conversely, two studies have reported an association
of GBA variants and an increased risk of developing
LIDs [9] or both LIDs and MF [15] when compared
to non-carriers. The first of these from Spain included
532 patients with PD recruited at a late disease stage
(on average > 10 years disease duration) and the date
of LIDs and MF onset was retrospectively obtained by
consulting previous medical records [15]. The Span-
ish cohort had a similar frequency of GBA carriers
(12.2%) but a substantially younger age of PD onset
(56 ± 12 years) compared to the current study. LIDs
were shown to develop earlier in carriers of benign
GBA variants (in this study including both synony-
mous and non-synonymous variants) (HR 2.4; 95%
CI 1.41 to 4.09; p = 0.001) and MF to develop ear-
lier in carriers of either benign GBA variants (HR
2.44; 95% CI 1.51 to 3.96; p < 0.001) or carriers of
severe GBA mutations (HR 1.85; 95% CI 1.22 to 2.81;
p = 0.004) [15]. Surprisingly, in this study the effect
on the development of MF was smaller for the more
damaging category of GBA mutations [15]. Subse-
quently, a population-based UK study prospectively
assessed the development of motor complications in
a total of 113 patients and found that whilst GBA
mutation status missed the threshold for significance
in unadjusted analysis (HR 2.75; 95% CI 0.94 to 8.0;
p = 0.064), GBA was associated with the development
of LIDs in multivariate analysis adjusted for baseline
MMSE score (HR 4.5; 95% CI 1.5 to 13.9: p = 0.009)
[9]. No associations were found with MF and given
the small number of participants and events observed,
this study may be too small to draw firm conclusions
regarding the association of GBA with LIDs or MF. In
the present study, in both in the European and Amer-
ican cohorts, GBA status had virtually no impact on
MF or LIDs with a HR close to one, indicating that
patients with GBA-associated PD are not at higher
risk of developing motor complications.
Despite the small number of studies that have
addressed the impact of GBA variants on the devel-
opment of motor complications, there is a striking
heterogeneity in their design. For example, the study
design (notably retrospective vs prospective follow
up and population-based vs specialist clinic settings),
cohort size, disease duration at recruitment, length
of follow up, methods used to detect motor compli-
cations (including UPDRS/MDS-UPDRS part IV or
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physicians’ diagnosis), and the criteria to select and
identify GBA variants, were different across the stud-
ies identified. Each of these factors can diminish the
capacity to compare the effects of GBA across differ-
ent studies and likely contribute to the differences in
the findings. This highlights the difficulty in assess-
ing the role of GBA variants in PD and advocates for
the validation of findings in longitudinal cohort stud-
ies designed specifically to study the progression of
PD.
Our study had several limitations. The modest
number of carriers of individual variants prevented
us from analyzing the effect of each variant sepa-
rately. Further, several cohorts were only screened for
selected GBA mutations and some individuals with
GBA variations (particularly severe mutations) were
probably missed, which could bias results toward the
null. However, the overall frequency of GBA vari-
ants detected in those cohorts analyzed using targeted
genotyping (PINE, 9.4%; NYPUM 15.0%) is similar
to those assessed with more comprehensive coverage
(PEG, 8.1%; ParkWest, 11.6%) and thus, these biases
can be expected to be minor. Similarly, we did not
account for other genetic variants, such as in LRRK2,
that are known to impact motor complications [45,
46] and the course of GBA-associated PD [47]. Fur-
thermore, a number PEG participants presented with
either MF or LIDs at their first clinical assessment.
This is not unexpected as PEG recruited patients up
to five years after PD diagnosis, and studies have
shown that motor complications may emerge as early
as several months to a few years after the initiation of
treatment [48]. Finally, the frequency of visits and the
duration of follow up in the PEG cohort was lower
than in the European studies, which could result in a
lower number of motor complication events detected.
Our study also had many important strengths, includ-
ing the use of large population-representative cohorts
and the prospective assessment of motor complica-
tions using uniform data-ascertainment methods for
more than 4000 study visits analyzed up to 11 years
from diagnosis, which address some of the weak-
nesses of previous studies. Furthermore, both the
European and PEG studies made substantial efforts to
follow participants until death, including home visits
for those no longer willing or able to attend clinic
visits, greatly reducing the problem of selection and
attrition bias. Finally, we used adjustment for impor-
tant confounders, including treatment-related factors
and were able to validate our findings from the Euro-
pean cohorts in an independent data set from the
USA.
CONCLUSION
In this study we do not find evidence that increased
risk of motor complications is a key feature of
GBA-associated PD but further studies in larger
population-based cohorts with comprehensive cov-
erage of GBA variants are needed to further clarify
the issue especially with regard to severity of the
mutations. The inclusion of negative findings in the
narrative of GBA-PD is vital to enable a balanced
assessment of the clinical features that may dif-
ferentially affect this subgroup of patients. A clear
understanding of the link between GBA-PD and MF
and LIDs is vital for proper patient management,
not least because decisions regarding current treat-
ment for those with GBA-PD may be influenced if
treatment-related motor complications would be con-
sidered as an important side effect among carriers.
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